NCI has established a program at Frederick National Laboratory to manufacture CAR T-cell therapies for multicenter clinical trials.
Pandemic notwithstanding, NCI is on track to reach the 15th percentile for the payline by 2025—a goal set by institute Director Ned Sharpless in response to a deluge of grant applications.
NCI has joined a nationwide initiative to increase the number of underrepresented minority faculty at NIH-funded cancer hospitals.
NCI plans to mark the 50th anniversary of the National Cancer Act of 1971 with an effort to build a coalition of support for cancer research, including raising the payline to 15% by 2025.
This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.
This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.
This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full directory of our coverage is available here.
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
The progress in cancer exceeds that of any other therapeutic area right now—at least as far as FDA is concerned, NCI Director Ned Sharpless said at a Dec. 3 joint meeting of the Board of Scientific Advisors and the National Cancer Advisory Board.
NCI is requesting an increase of $989 million to its FY2021 budget over FY2019 appropriated levels to boost the institute's payline, which has dropped to the 8th percentile in FY19—lower than 2013 sequestration levels—and which has been steadily dropping despite increased overall funding in recent years.
